Helena Smolak
Reporter, Real-Time EMEA News Desk at The Wall Street Journal
Journalist @WSJ chasing breaking news & hidden stories. Former Investigator @WFP @UN. Alumna @MediaLSE. For tips: [email protected]. Views my own.
Articles
-
1 month ago |
tradingview.com | Helena Smolak
Merck KGaA Shares Plunge After Outlook Cut on Tariff, Currency RisksMRKGermany's Merck KGaA shares plunged after the company slashed its full-year outlook on the back of uncertainty around tariffs and foreign-exchange headwinds. In European morning trading shares were down 5.6% at 116.95 euros. The stock is down 16% since the start of the year.
-
1 month ago |
wsj.com | Helena Smolak
Profit after tax rose to €738 million in the first quarter from €699 million in the prior year periodThe life-sciences and electronics company said Thursday that it now expects full-year sales to come in between 20.9 billion and 22.4 billion euros ($23.35 billion-$25.03 billion), previously forecast at between 21.5 billion and 22.9 billion euros.
-
1 month ago |
tradingview.com | Helena Smolak
Merck KGaA Cuts Outlook Amid Macroeconomic ChallengesMRKGermany's Merck KGaA slashed its full-year outlook on the back of challenging macroeconomic conditions and foreign-exchange headwinds. The life-sciences and electronics company said Thursday that it now expects full-year sales to come in between 20.9 billion and 22.4 billion euros ($23.35 billion-$25.03 billion), previously forecast at between 21.5 billion and 22.9 billion euros.
-
1 month ago |
finance.yahoo.com | Helena Smolak
GSK will acquire a liver-disease treatment from Boston Pharmaceuticals as it seeks to boost its pipeline of new drugs. - chris j ratcliffe/Reuters GSK will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs. The British pharma giant said Wednesday that it will pay the U.S. biotech company $1.2 billion upfront, with a further $800 million in potential success-based milestone payments.
-
1 month ago |
wsj.com | Helena Smolak
Efimosfermin is currently in late-stage trials and could potentially go to market in 2029The British pharma giant said Wednesday that it will pay the U.S. biotech company $1.2 billion up-front, and that the deal includes potential success-based milestone payments of $800 million. Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8Subscribe NowAlready a subscriber? Sign In
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 85
- Tweets
- 78
- DMs Open
- No
RT @domchopping: https://t.co/0Udb3AHRBF
I spoke with @Novartis 's CEO about why his appetite for obesity deals isn't over yet - and how the Swiss pharma giant plans to bridge its pipeline gap between 2027 to 2030.
Novartis has set a high bar for any potential obesity-treatment acquisition as it scans the market for deals to fill its drug pipeline and power sales growth into the 2030s https://t.co/Xrg7IxdeIF
Pharma's bet on #AI to advance drug development seems promising but there are hurdles and the biggest aren't even technological. Technology is not the primary bottleneck preventing faster progress; it’s largely operational and cultural challenges. My latest analysis:
Pharma Companies Turn to AI to Speed Up Drug Development, But Hit Hurdles https://t.co/0RinbBqGhH